NASDAQ:ABVX Abivax Q3 2025 Earnings Results & Report $83.61 -3.97 (-4.53%) Closing price 04:00 PM EasternExtended Trading$83.52 -0.09 (-0.11%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Abivax reported Q3 2025 earnings on December 15, 2025. The company reported EPS of -$2.46, while revenue was -$4.92 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateDecember 15, 2025TimeAfter Market ClosesConference Call11:45 AM ET Abivax EPS ResultsActual EPS-$2.46Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEPS Beat Rate3 of last 4 quartersAbivax Revenue ResultsActual Revenue-$4.92 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsAbivax's Q3 2026 earnings is estimated for Monday, December 21, 2026, based on past reporting schedules, with a conference call scheduled on Monday, December 14, 2026 at 3:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (6-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(6-K) Abivax Q3 2025 Earnings FAQ Did Abivax beat earnings estimates for Q3 2025? Abivax (NASDAQ:ABVX) reported earnings of -$2.46 per share for Q3 2025. The report was announced on Monday, December 15, 2025. What was Abivax's revenue for Q3 2025? Abivax reported revenue of -$4.92 million for Q3 2025. When is Abivax's next earnings date? Abivax's next earnings date is estimated for Monday, December 21, 2026. MarketBeat tracks confirmed and estimated earnings dates for Abivax on the company's earnings history page. Abivax Earnings HeadlinesAbivax SA Sponsored ADR (ABVX) - What Are Investment Firms Thinking About This Stock?November 10, 2026 | americanbankingnews.comAbivax to Participate in Upcoming Fall Investor ConferencesNovember 2, 2026 | globenewswire.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.November 16 at 1:00 AM | Weiss Ratings (Ad)Abivax SA ADR ABVXOctober 23, 2026 | morningstar.comMAbivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026September 30, 2026 | markets.businessinsider.comABIVAX Société Anonyme (ENXTPA:ABVX) Appoints New Chief Medical And Technical OfficersSeptember 26, 2026 | finance.yahoo.comSee More Abivax Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Abivax? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Abivax and other key companies, straight to your email. Email Address About AbivaxAbivax (NASDAQ:ABVX) is a clinical-stage biopharmaceutical company headquartered in Paris, France. It develops treatments for chronic inflammatory diseases, with a focus on therapies that regulate the body’s immune response. The company’s lead candidate, obefazimod (formerly known as ABX464), is an oral small molecule being studied for ulcerative colitis and other inflammatory conditions. It is designed to increase production of miR-124, a molecule involved in regulating inflammation. Founded in 2013, Abivax conducts clinical development internationally. Marc de Garidel has served as the company’s chief executive officer.View Abivax ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/133 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCould Big Buybacks Be the Next Catalyst for These 3 AI Stocks?Cerebras Q3 Results: How Much More Proof Does Wall Street Need? Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.